1. Home
  2. PCVX vs HLNE Comparison

PCVX vs HLNE Comparison

Compare PCVX & HLNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vaxcyte Inc.

PCVX

Vaxcyte Inc.

N/A

Current Price

$56.25

Market Cap

6.1B

Sector

Health Care

ML Signal

N/A

Logo Hamilton Lane Incorporated

HLNE

Hamilton Lane Incorporated

N/A

Current Price

$94.08

Market Cap

4.7B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
PCVX
HLNE
Founded
2013
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
6.1B
4.7B
IPO Year
2020
2017

Fundamental Metrics

Financial Performance
Metric
PCVX
HLNE
Price
$56.25
$94.08
Analyst Decision
Strong Buy
Buy
Analyst Count
7
9
Target Price
$98.33
$168.33
AVG Volume (30 Days)
1.0M
799.3K
Earning Date
05-27-2026
05-04-2026
Dividend Yield
N/A
2.20%
EPS Growth
N/A
41.64
EPS
N/A
3.98
Revenue
N/A
$712,963,000.00
Revenue This Year
N/A
$9.81
Revenue Next Year
N/A
$19.69
P/E Ratio
N/A
$24.65
Revenue Growth
N/A
28.73
52 Week Low
$28.09
$96.00
52 Week High
$76.61
$179.19

Technical Indicators

Market Signals
Indicator
PCVX
HLNE
Relative Strength Index (RSI) 48.83 24.83
Support Level $42.30 N/A
Resistance Level $57.50 $157.95
Average True Range (ATR) 2.96 4.98
MACD -0.68 -0.17
Stochastic Oscillator 14.14 8.30

Price Performance

Historical Comparison
PCVX
HLNE

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

About HLNE Hamilton Lane Incorporated

Hamilton Lane Inc is a private markets investment firm globally, providing solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 750 professionals operating in offices throughout North America, Europe, Asia Pacific, and the Middle East. It has approximately $986 billion in assets under management and supervision, composed of nearly $141 billion in discretionary assets and more than $845 billion in non-discretionary assets. The group specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors, and geographies.

Share on Social Networks: